Pfizer Says Expected Decline in Paxlovid and Comirnaty Revenues Drove 41% Operational Decrease in Q3 FY23 Revenues
Portfolio Pulse from Benzinga Newsdesk
Pfizer has reported a 41% operational decrease in Q3 FY23 revenues, attributing the decline to expected lower revenues from Paxlovid and Comirnaty.
October 31, 2023 | 10:54 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Pfizer's Q3 FY23 revenues have decreased by 41% due to expected lower revenues from Paxlovid and Comirnaty.
The news directly mentions Pfizer and its products Paxlovid and Comirnaty. The significant decrease in revenues is likely to negatively impact the company's stock price in the short term as it indicates a decrease in sales of its key products.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100